Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, parallel group, open-label, multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anaemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific

Trial Profile

A randomized, parallel group, open-label, multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anaemia in pre-dialysis subjects with chronic kidney disease on darbepoetin treatment in Europe and Asia Pacific

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molidustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms DIALOGUE 2
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 11 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 09 Jul 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top